Perioperative management of high-risk corneal transplantation using basiliximab and mycophenolate mofetil

Can J Ophthalmol. 2023 Aug;58(4):e166-e168. doi: 10.1016/j.jcjo.2022.12.009. Epub 2023 Jan 15.

Authors

Cameron B Reinisch¹, Asma M Azam², Albert Y Cheung³, Amit Govil¹, Edward J Holland⁴

Affiliations

¹ University of Cincinnati, Cincinnati, Ohio.
² Eastern Virginia Medical School, Norfolk, VA.
³ Eastern Virginia Medical School, Norfolk, VA; Virginia Eye Consultants/CVP Physicians, Norfolk, VA.
⁴ University of Cincinnati, Cincinnati, Ohio; Cincinnati Eye Institute, Edgewood, KY. Electronic address: [email protected].

PMID: 36649916
DOI: 10.1016/j.jcjo.2022.12.009

No abstract available

Publication types

Letter

MeSH terms

Basiliximab
Drug Therapy, Combination
Graft Rejection / prevention & control
Humans
Immunosuppressive Agents* / therapeutic use
Mycophenolic Acid* / therapeutic use
Recombinant Fusion Proteins

Substances

Basiliximab
Mycophenolic Acid
Immunosuppressive Agents
Recombinant Fusion Proteins